A Phase I, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination With Durvalumab in Patients With Advanced Solid Malignancies

What is the purpose of this trial?

This is a Phase I, open-label, multicenter study of continuous oral dosing of AZD4635 administered as a single agent and then in combination with a PD-L1 antibody, durvalumab. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of the patients. The primary objective of the study is to determine the maximum tolerated dose of AZD4635 in combination with durvalumab.

Astra Zeneca, L.P.

Start Date: 10/10/2018

End Date: 05/01/2020

Last Updated: 10/21/2018

Study HIC#: 2000023248

Get Involved

For more information about this study, contact:
Nicole Sinclair
+1 203-737-1889

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image